Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer.
- DOI
- 10.1016/j.gore.2019.07.010
- Published
- 2019 Aug
- Container
- Gynecologic oncology reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.gore.2019.07.010,
title = {Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer.},
author = {Lee EK and Tan-Wasielewski Z and Matulonis UA and Birrer MJ and Wright AA and Horowitz N and Konstantinopoulos PA and Curtis J and Liu JF},
year = {2019},
journal = {Gynecologic oncology reports},
doi = {10.1016/j.gore.2019.07.010},
url = {https://doi.org/10.1016/j.gore.2019.07.010}
}RIS
TY - JOUR TI - Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. AU - Lee EK AU - Tan-Wasielewski Z AU - Matulonis UA AU - Birrer MJ AU - Wright AA AU - Horowitz N AU - Konstantinopoulos PA AU - Curtis J AU - Liu JF PY - 2019 JO - Gynecologic oncology reports DO - 10.1016/j.gore.2019.07.010 UR - https://doi.org/10.1016/j.gore.2019.07.010 ER -
APA
EK, L., Z, T., UA, M., MJ, B., AA, W., N, H., PA, K., J, C., & JF, L. (2019). Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer.. Gynecologic oncology reports. https://doi.org/10.1016/j.gore.2019.07.010
Source records
- pubmed · retrieved 2026-09-27T08:34:26.932Z